Published in Cancer Weekly, August 14th, 2001
The study is designed to determine the safety and maximum tolerated dose of cisplatin when administered with Triapine in patients with advanced cancer. The study is currently open at the Arizona Clinical Research Center in Tucson, Arizona. Triapine is a potent inhibitor of the enzyme ribonucleotide reductase. In preclinical studies, Triapine inhibits DNA synthesis, slows or stops cancer cell division, and disrupts repair of DNA damage caused by several standard anti-cancer agents including cisplatin.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.